45434-73-9

Basic information

• Product Name: 3,4-Furandiamine,tetrahydro-,(3S,4S)-(9CI)
• Synonyms: 3,4-Furandiamine,tetrahydro-,(3S,4S)-(9CI);(3S,4S)-3,4-TetrahydrofurandiaMine;(3S,4S)-oxolane-3,4-diamine;(3S,4S)-Tetrahydrofuran-3,4-diamine
• CAS NO: 45434-73-9
• Molecular Formula: C4H10N2O
• Molecular Weight: 102.14
• Product Categories: VARIOUSAMINE
• Mol File: 45434-73-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3,4-Furandiamine,tetrahydro-,(3S,4S)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Furandiamine,tetrahydro-,(3S,4S)-(9CI)(45434-73-9)
• EPA Substance Registry System: 3,4-Furandiamine,tetrahydro-,(3S,4S)-(9CI)(45434-73-9)

Safety Data

• Hazardous Substances Data: 45434-73-9(Hazardous Substances Data)

Usage

General Description

3,4-Furandiamine, tetrahydro, (3S,4S)-(9CI) is a chemical compound with the molecular formula C4H10N2O. It is a tetrahydro derivative of 3,4-Furandiamine and is composed of an organic ring structure with two amine groups. This chemical is not very common and is primarily used in research and experimental settings. It has potential applications in the field of organic synthesis and may be used as a building block for the creation of other organic compounds. Its specific properties and potential uses in various industries have not been extensively studied, and further research may be necessary to fully understand its potential applications.

Upstream product

• 167937-18-0 (S,S)-trans-3,4-diazidotetrahydrofuran 

Downstream Products

• 1330763-30-8 (4-aminotetrahydrofuran-3-yl)carbamic acid tert-butyl ester 

Relevant articles and documents

3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS

The invention provides certain 3-pyridyl carboxamide-containing compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.